{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:00Z","timestamp":1793963040901,"version":"4.8.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Many chronic inflammatory diseases are treated by administration of \u201cbiological\u201d therapies in terms of fully human and humanized monoclonal antibodies or Fc fusion proteins. These tools have widespread efficacy and are favored because they generally exhibit high specificity for target with a low toxicity. However, the design of clinically applicable humanized antibodies is complicated by the need to circumvent normal antibody clearance mechanisms to maintain therapeutic dosing, whilst avoiding development of off target antibody dependent cellular toxicity. Classically, professional phagocytic immune cells are responsible for scavenging and clearance of antibody<jats:italic>via<\/jats:italic>interactions with the Fc portion. Immune cells such as macrophages, monocytes, and neutrophils express Fc receptor subsets, such as the Fc\u03b3R that can then clear immune complexes. Another, the neonatal Fc receptor (FcRn) is key to clearance of IgG<jats:italic>in vivo<\/jats:italic>and serum half-life of antibody is explicitly linked to function of this receptor. The liver is a site of significant expression of FcRn and indeed several hepatic cell populations including Kupffer cells and liver sinusoidal endothelial cells (LSEC), play key roles in antibody clearance. This combined with the fact that the liver is a highly perfused organ with a relatively permissive microcirculation means that hepatic binding of antibody has a significant effect on pharmacokinetics of clearance. Liver disease can alter systemic distribution or pharmacokinetics of antibody-based therapies and impact on clinical effectiveness, however, few studies document the changes in key membrane receptors involved in antibody clearance across the spectrum of liver disease. Similarly, the individual contribution of LSEC scavenger receptors to antibody clearance in a healthy or chronically diseased organ is not well characterized. This is an important omission since pharmacokinetic studies of antibody distribution are often based on studies in healthy individuals and thus may not reflect the picture in an aging or chronically diseased population. Therefore, in this review we consider the expression and function of key antibody-binding receptors on LSEC, and the features of therapeutic antibodies which may accentuate clearance by the liver. We then discuss the implications of this for the design and utility of monoclonal antibody-based therapies.<\/jats:p>","DOI":"10.3389\/fphys.2021.753833","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T05:41:25Z","timestamp":1642138885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody"],"prefix":"10.3389","volume":"12","author":[{"given":"Bethany H.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelitsa","family":"Papakyriacou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gardener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Gliddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia F.","family":"Lalor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijpharm.2013.01.001","article-title":"Application of knockout mouse models to investigate the influence of FcgammaR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody.","volume":"444","author":"Abuqayyas","year":"2013","journal-title":"Int. J. Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/039463201202500311","article-title":"Influence of experimental alcohol administration on serum immunoglobulin levels: contrasting effects on IgE and other immunoglobulin classes.","volume":"25","author":"Alonso","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1053\/j.gastro.2004.09.089","article-title":"Anti-TNF therapy for severe acute alcoholic hepatitis: what went wrong?","volume":"127","author":"Blendis","year":"2004","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1084\/jem.170.4.1369","article-title":"Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes.","volume":"170","author":"Brooks","year":"1989","journal-title":"J. Exp. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/liv.13649","article-title":"Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis.","volume":"38","author":"Cacciola","year":"2018","journal-title":"Liver Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway.","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/s41467-020-15584-3","article-title":"The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure.","volume":"11","author":"Chauhan","year":"2020","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"H1064","DOI":"10.1152\/ajpheart.00949.2015","article-title":"Dietary macronutrients and the aging liver sinusoidal endothelial cell.","volume":"310","author":"Cogger","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1124\/dmd.119.086488","article-title":"Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides.","volume":"47","author":"Datta-Mannan","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"B12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/19420862.2016.1178435","article-title":"Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.","volume":"8","author":"Datta-Mannan","year":"2016","journal-title":"MAbs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1074\/jbc.M607161200","article-title":"Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.","volume":"282","author":"Datta-Mannan","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/1547691X.2011.613419","article-title":"A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.","volume":"9","author":"Dhir","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0047-6374(90)90003-X","article-title":"Binding and uptake of ligands for mannose-specific receptors in liver cells: an electron microscopic study during development and aging in rat.","volume":"56","author":"Dini","year":"1990","journal-title":"Mech. Ageing Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/eji.201847924","article-title":"Human Fcgamma receptors compete for TGN1412 binding that determines the antibody\u2019s effector function.","volume":"49","author":"Dudek","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0168-8278(00)80412-2","article-title":"Liver regeneration.","volume":"32","author":"Fausto","year":"2000","journal-title":"J. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","article-title":"FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes.","volume":"189","author":"Ganesan","year":"2012","journal-title":"J. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.virol.2007.11.001","article-title":"Interactions of LSECtin and DC-SIGN\/DC-SIGNR with viral ligands: differential pH dependence, internalization and virion binding.","volume":"373","author":"Gramberg","year":"2007","journal-title":"Virology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/978-3-7091-1065-2_36","author":"Gupta","year":"2012","journal-title":"DC-SIGN Family of Receptors, Animal Lectins: Form, Function and Clinical Applications."},{"key":"B21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies.","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dmpk.2018.10.003","article-title":"Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering.","volume":"34","author":"Haraya","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/gut.23.9.724","article-title":"Demonstration of non-specific B-cell stimulation in patients with cirrhosis.","volume":"23","author":"Holdstock","year":"1982","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"G144","DOI":"10.1152\/ajpgi.00179.2018","article-title":"Manipulating fenestrations in young and old liver sinusoidal endothelial cells.","volume":"316","author":"Hunt","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial.","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000024347","article-title":"IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes.","volume":"121","author":"Johansson","year":"2000","journal-title":"Int. Arch. Allergy Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12257-020-0181-8","article-title":"Development of therapeutic antibodies and modulating the characteristics of therapeutic antibodies to maximize the therapeutic efficacy.","volume":"26","author":"Kang","year":"2021","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"B31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020.","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"I70","DOI":"10.1136\/ard.58.2008.i70","article-title":"Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.","volume":"58","author":"Kempeni","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1471-4906(01)01957-3","article-title":"Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells.","volume":"22","author":"Knolle","year":"2001","journal-title":"Trends Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/eji.1830060411","article-title":"Fusion between immunoglobulin-secreting and non-secreting myeloma cell lines.","volume":"629","author":"Kohler","year":"1976","journal-title":"Eur. J. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.omtm.2017.08.006","article-title":"In Situ liver expression of HBsAg\/CD3-bispecific antibodies for HBV immunotherapy.","volume":"7","author":"Kruse","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.314668","article-title":"Monoclonal antibodies defining distinctive human T cell surface antigens.","volume":"206","author":"Kung","year":"1979","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0231655","DOI":"10.1371\/journal.pone.0231655","article-title":"Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates.","volume":"15","author":"Laffan","year":"2020","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2353\/ajpath.2006.051191","article-title":"Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles.","volume":"169","author":"Lai","year":"2006","journal-title":"Am. J. Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues.","volume":"65","author":"Latvala","year":"2017","journal-title":"J. Histochem. Cytochem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cts.12597","article-title":"Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies.","volume":"12","author":"Leipold","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4161\/mabs.29809","article-title":"Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.","volume":"6","author":"Li","year":"2014","journal-title":"MAbs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1208698109","article-title":"Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement.","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"G71","DOI":"10.1152\/ajpgi.00215.2010","article-title":"Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins.","volume":"300","author":"Li","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0122739","DOI":"10.1371\/journal.pone.0122739","article-title":"The injured liver induces hyperimmunoglobulinemia by failing to dispose of antigens and endotoxins in the portal system.","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(90)90457-7","article-title":"Hepatic immune complex elimination studied with FITC-labelled antigen.","volume":"128","author":"Ljunghusen","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"B48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/368856a0","article-title":"Antigen-specific human antibodies from mice comprising four distinct genetic modifications.","volume":"368","author":"Lonberg","year":"1994","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/368856a0","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-alpha on the liver.","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3390\/ijms19082199","article-title":"Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver.","volume":"113","author":"Lovdal","year":"2000","journal-title":"J. Cell Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/jcs.113.18.3255","article-title":"Development of therapeutic antibodies for the treatment of diseases.","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-019-0592-z","article-title":"Factors affecting the pharmacology of antibody-drug conjugates.","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/CPAA.S24004","article-title":"Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.","volume":"3","author":"Mahamid","year":"2011","journal-title":"Clin. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains.","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0297-146","article-title":"Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice.","volume":"15","author":"Mendez","year":"1997","journal-title":"Nat. Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/gerona\/glq221","article-title":"Age-related pseudocapillarization of the liver sinusoidal endothelium impairs the hepatic clearance of acetaminophen in rats.","volume":"66","author":"Mitchell","year":"2011","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpba.2009.07.013","article-title":"HAHA\u2013nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.","volume":"51","author":"Nechansky","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/00313021003636469","article-title":"The effect of feeding and fasting on fenestrations in the liver sinusoidal endothelial cell.","volume":"42","author":"O\u2019Reilly","year":"2010","journal-title":"Pathology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1733876","article-title":"Scavenger receptors: novel roles in the pathogenesis of liver inflammation and cancer.","author":"Patten","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"E2862","DOI":"10.1073\/pnas.1618291114","article-title":"Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.","volume":"114","author":"Pyzik","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity.","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns.","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration.","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy.","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age.","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"F947","DOI":"10.1152\/ajprenal.90601.2008","article-title":"Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier.","volume":"296","author":"Satchell","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hon.2858","article-title":"Bispecific antibodies for the treatment of lymphomas: promises and challenges.","volume":"39","author":"Schuster","year":"2021","journal-title":"Hematol. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/00002030-199307000-00003","article-title":"Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies.","volume":"7","author":"Schutten","year":"1993","journal-title":"AIDS"},{"key":"B71","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.celrep.2015.09.013","article-title":"Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice.","volume":"13","author":"Schwab","year":"2015","journal-title":"Cell Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody.","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0300-483X(95)03123-W","article-title":"Side-effects of a monoclonal antibody, muromonab CD3\/orthoclone OKT3: bibliographic review.","volume":"105","author":"Sgro","year":"1995","journal-title":"Toxicology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2008.10.024","article-title":"Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial.","volume":"50","author":"Sharma","year":"2009","journal-title":"J. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/aging.100652","article-title":"Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.","volume":"6","author":"Sheedfar","year":"2014","journal-title":"Aging (Albany NY)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity.","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B78","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.4049\/jimmunol.163.11.6236","article-title":"Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.","volume":"163","author":"Shields","year":"1999","journal-title":"J. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/gerona\/glq108","article-title":"Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells.","volume":"65","author":"Simon-Santamaria","year":"2010","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"B80","first-page":"585","article-title":"Hepatic uptake of circulating IgG immune complexes.","volume":"55","author":"Skogh","year":"1985","journal-title":"Immunology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1186\/1476-5926-2-S1-S22","article-title":"Clearance function of scavenger endothelial cells.","volume":"3","author":"Smedsrod","year":"2004","journal-title":"Comp. Hepatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10875-016-0247-8","article-title":"Regulation of Monoclonal Antibody Immunotherapy by FcgammaRIIB.","volume":"36","author":"Stopforth","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cpt.1765","article-title":"Does hepatic impairment affect the exposure of monoclonal antibodies?","volume":"107","author":"Sun","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14740330802500353","article-title":"The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice.","volume":"7","author":"Tamhane","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"B88","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab.","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymeth.2005.01.007","article-title":"Design of humanized antibodies: from anti-Tac to Zenapax.","volume":"36","author":"Tsurushita","year":"2005","journal-title":"Methods"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies.","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.4049\/jimmunol.1301430","article-title":"Immunotherapy targeting inhibitory Fcgamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.","volume":"191","author":"Williams","year":"2013","journal-title":"J. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.4049\/jimmunol.0804182","article-title":"Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.","volume":"182","author":"Yeung","year":"2009","journal-title":"J. Immunol."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.753833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T22:50:19Z","timestamp":1674427819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.753833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":93,"alternative-id":["10.3389\/fphys.2021.753833"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.753833","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"753833"}}